<DOC>
	<DOCNO>NCT00803972</DOCNO>
	<brief_summary>This single center , Phase I , open-label , single-blind ( subject blind content injection ) , 4 stage study design determine PK , GD , safety , tolerability , optimal ratio rHuPH20 administer fix Humulin R Humalog dose healthy subject .</brief_summary>
	<brief_title>Dose-Ranging , Pharmacokinetic ( PK ) , Glucodynamic ( GD ) , Safety Tolerability Study Subcutaneously ( SC ) Administered Humulin R Humalog With Without rHuPH20</brief_title>
	<detailed_description>Subjects enrol one four sequential study stage . In stage , euglycemic clamp procedure use control plasma glucose level . Blood sample collect 8-hour time period insulin administration ( either Humulin R Humalog ) analyze insulin glucose level use fully validate method . Glucose infusion rate ( GIR ) record throughout study period . The study single-blind , study subject blind content injection . Determine pharmacokinetics ( PK ) optimum ratio rHuPH20 : insulin range rHuPH20 dose ratio administer subcutaneously ( SC ) fix dos Humulin R , determine Tmax , Cmax , AUCs , relative bioavailability base serum insulin concentration collect specified time point ( Stage 1 ) . Determine different concentration Humulin R impact PK minimal rHuPH20 dose necessary achieve full insulin PK effect representative range typical prandial SC Humulin R dose use rHuPH20 : insulin ratio identify Stage 1 ( Stage 2 ) . Determine PK optimum ratio rHuPH20 : insulin range rHuPH20 dose ratio administer SC fixed dos Humalog , determine Tmax , Cmax , AUCs , relative bioavailability base serum insulin concentration collect specified time point ( Stage 3 ) . Determine different concentration Humalog impact PK minimal rHuPH20 dose necessary achieve full insulin PK effect representative range typical prandial SC Humalog dose use rHuPH20 : insulin ratio identify Stage 3 ( Stage 4 ) . Evaluate safety local tolerability SC injection various rHuPH20 , Humulin R , Humalog dose ( Stages 1 - 4 ) . Assess glucodynamics ( GD ) SC injection various rHuPH20 , Humulin R , Humalog dose ( Stages 1 - 4 ) .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Healthy subject age 18 55 year , inclusive . ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination ( PE ) , include blood pressure ( BP ) heart rate ( HR ) , 12lead electrocardiogram ( ECG ) clinical laboratory test specify eligibility criterion ) . BMI 1828 kg/m2 , inclusive . Total body weight &gt; 70 kg ( 154 lb ) men 46 kg ( 101 lb ) woman . Subject willing able comply schedule visit , treatment plan , laboratory test , study procedure include adequate venous access . Vital sign ( BP , HR , temperature , respiratory rate ) within normal range , range , assess Principal Investigator ( PI ) clinically significant ( NCS ) mutually agree PI Sponsor 's medical monitor subject need exclude study abnormal value . Within 14 day first injection : metabolic panel ( e.g. , sodium , potassium , chloride , bicarbonate , BUN ( blood urea nitrogen ) , creatinine , glucose , calcium , AST ( aspartate transaminase [ SGOT ] ) , ALT ( alanine transaminase [ SGPT ] ) , alkaline phosphatase , total bilirubin , albumin , cholesterol , lipid , amylase total protein ) complete blood count ( CBC ) within laboratory normal reference range , range , assess PI NCS mutually agree PI Sponsor 's medical monitor subject need exclude study laboratory value . Fasting plasma glucose level within range 60 100 mg/dL , inclusive , within 30 minute first euglycemic clamp . A negative serum pregnancy test ( female childbearing potential ) within 14 day study drug injection . Female subject childbearing potential must agree practice effective birth control abstinence currently agree continue duration time study . Decisionmaking capacity willingness ability comply requirement full completion study . Signed , write IRBapproved informed consent . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , oncologic , neurologic ( include history seizure ) disease ; hypoglycemic episode ; intercurrent illness ( influenza ) ; allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Clinical significance determine PI . Known history diabetes mellitus gestational diabetes . Known allergy hyaluronidase ingredient study drug . Positive HIV 1 HIV 2 ( human immunodeficiency virus ) antibody test , hepatitis B ( antiHBsAg ) hepatitis C ( antiHCV ) antibody test . Any history evidence alcohol drug abuse . History evidence use tobacco nicotinecontaining product within 6 month screen , screen quantitative urine nicotine concentration &gt; 50 ng/mL , screen serum cotinine concentration &gt; 20 ng/mL . Use drug may interfere interpretation trial result know cause clinically relevant interference insulin action glucose utilization . Donation blood excess 500 mL within 56 day dose . Failure limit alcohol consumption refrain exercise within 48 hour injection . Participation study investigational drug device 30 day enrollment study . The subject unfit study opinion investigator . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Humalog</keyword>
	<keyword>Humulin R</keyword>
	<keyword>rHuPH20</keyword>
	<keyword>Hylenex</keyword>
</DOC>